Veriton Pharma
- Company typePrivate
- Founded1997
- HeadquartersWeybridge, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Veriton Pharma firmographics
Firmographics- Name
- Veriton Pharma
- Legal name
- Veriton Pharma Limited
- Website
- https://veritonpharma.com
- Company type
- Private
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Veriton Pharma industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
- akta.pro secondary industry
- Specialty Pharmacies (Complex/High-Cost Therapies) (HLAFALAC)
Keywords
Where Veriton Pharma is headquartered
LocationHeadquarters
- HQ city
- Weybridge
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
Veriton Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure
Veriton Pharma product offering
Product offeringCore offering
Veriton Pharma supplies both unlicensed and licensed medicinal products to support patient care. Operating as a UK-registered subsidiary brand under SERB Pharmaceuticals, the company provides medicines for the treatment of complex and life-threatening conditions, distributing through established pharmaceutical supply channels used by its parent group.
Product overview
The source data pertains to SERB Pharmaceuticals, a global specialty pharmaceutical company. Veriton Pharma is mentioned solely as a registered trademark owned by Veriton Pharma Limited, appearing in the footer as a trademark of SERB's parent entity. No specific products, services, or product details for Veriton Pharma are provided in the source content.
Differentiator
Problem solved
Functional benefit
Products and services
- Unlicensed medicinal products Unlicensed medicinal products supplied by Veriton Pharma to address patient needs where a fully licensed alternative is not available, supporting healthcare providers in treating complex and life-threatening conditions.
- Licensed medicinal products Licensed medicinal products supplied by Veriton Pharma as part of its specialty pharmaceutical offering, complementing its unlicensed product supply and supporting healthcare providers treating complex and life-threatening conditions.
Companies that use Veriton Pharma
Customer profileIdeal customer profiles1 record
Veriton Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Veriton Pharma partnerships and signals
Strategic signalRecent moves4 records
Expansion highlights3 records
Veriton Pharma competitors and assessment
Company assessmentDirect peers
- Clinigen Group: UK-headquartered specialty pharmaceutical company focused on access to unlicensed, 'specials' and rare-disease medicines. Directly comparable to Veriton on the niche of supplying both licensed and unlicensed medicines into UK hospital and pharmacy channels.
- Quantum Pharmaceutical (part of Clinigen): UK specials manufacturer and distributor of unlicensed and licensed medicines to pharmacies and hospitals. Closely comparable to Veriton on the regulated UK unlicensed-medicines supply proposition.
- BCM Specials (BCM Group): UK-based manufacturer and supplier of unlicensed 'specials' medicines and a range of named-patient and licensed products. Direct peer to Veriton in the UK unlicensed-medicines channel serving pharmacy and hospital customers.
- Mawdsley Brothers: UK pharmaceutical services company specializing in unlicensed medicines, specials manufacturing, and bespoke pharmacy supplies. Overlapping value proposition with Veriton's combined licensed/unlicensed offering.
Broad incumbents
- SERB Pharmaceuticals: Direct parent of Veriton Pharma; a global specialty pharmaceutical company with antidotes, CBRN countermeasures, and rare-disease medicines across 100+ countries. Comparable as the broader specialty/rare-disease platform that Veriton sits within.
- Swedish Orphan Biovitrum (Sobi): Specialty and rare-disease pharmaceutical company operating across Europe and North America. Comparable to Veriton/SERB on the focus on complex, niche specialty therapeutics that require dedicated supply infrastructure.
- Recordati: European specialty pharmaceutical company with a dedicated rare-disease business. Comparable to the SERB/Veriton combination on rare-disease and specialty therapeutic orientation.
- Emergent BioSolutions: Specialty biopharmaceutical company focused on medical countermeasures, antidotes and CBRN preparedness. Directly comparable to SERB's portfolio and therefore to the emergency-medicine end of Veriton's parent offering.
- Aspen Pharmacare (UK operations): Global specialty pharma group with a significant UK and European off-patent and specialty portfolio. Comparable as a broader incumbent active in UK specialty pharmaceutical supply.
Regional players
- Accord Healthcare (Intas Group): European-focused specialty and generics pharmaceutical company with a strong UK hospital-channel presence. Comparable on the model of a private specialty pharma operating across multiple European markets, though with a generics rather than unlicensed-medicines emphasis.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
Veriton Pharma social profiles
Digital presenceVeriton Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Veriton Pharma leadership team
Management profileNumber of profiles
Veriton Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Veriton Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Veriton Pharma
What does Veriton Pharma do?
Veriton Pharma supplies both unlicensed and licensed medicinal products to support patient care. Operating as a UK-registered subsidiary brand under SERB Pharmaceuticals, the company provides medicines for the treatment of complex and life-threatening conditions, distributing through established pharmaceutical supply channels used by its parent group.
Is Veriton Pharma a public or private company?
Veriton Pharma is a private company. It is classified as corporate owned and is currently operating.
When was Veriton Pharma founded?
Veriton Pharma was founded in 1997. It employs 11 to 50 people.
Where is Veriton Pharma based?
Veriton Pharma is headquartered in Weybridge, United Kingdom, in the Europe region.
Who are Veriton Pharma's main competitors?
Direct peers on record are Clinigen Group, Quantum Pharmaceutical (part of Clinigen), BCM Specials (BCM Group) and Mawdsley Brothers. Broad incumbents are SERB Pharmaceuticals, Swedish Orphan Biovitrum (Sobi), Recordati, Emergent BioSolutions and Aspen Pharmacare (UK operations). Accord Healthcare (Intas Group) is listed as a regional player.
Does Veriton Pharma have an API?
No public API is recorded for Veriton Pharma.
What industry is Veriton Pharma in?
Veriton Pharma's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAFALAC, Specialty Pharmacies (Complex/High-Cost Therapies). Its NAICS code is 325412 and its SIC code is 2834.